Results From the First and Largest Collaborative Study Confirm Role of Enbrel(R) in Psoriatic Arthritis

Geschrieben am 04-12-2008

Maidenhead, England (ots/PRNewswire) -

- New Data Add to the Body of Evidence That Show That Enbrel
(Etanercept) Clears Skin and Can Sustain This Efficacy Over Time

New data presented today at the 'Gene to Clinic' meeting taking
place at the Royal College of Physicians in London, England,
reinforce Enbrel's ability to clear skin in patients with psoriatic
arthritis, an inflammatory and progressive disease associated with
psoriasis. Results from the pioneering PRESTA (Psoriasis Randomized
Etanercept STudy in Subjects with Psoriatic Arthritis) study showed
that at 24 weeks, two out of three patients with psoriatic arthritis
(70% taking 50mg Enbrel twice-weekly and 62% taking 50mg once-weekly)
showed a 75% improvement in the psoriasis area-and-severity index
(PASI 75)(1). PRESTA is the first and largest study of its kind where
both dermatologists and rheumatologists have come together to
investigate the positive effects of Enbrel in this specific patient

To view the Multimedia News Release, please click:

Psoriatic arthritis is an inflammatory disease that affects both
the skin and joints, where the skin symptoms usually appear before
the joint symptoms. Despite the potentially serious impact of the
disease, it is difficult to make an accurate diagnosis.

Prof Wolfram Sterry, PRESTA study investigator and Director of
the Clinic for Dermatology, Venereology and Allergology at the
Charité Berlin, Germany, says: "Up to 40% of psoriasis patients will
go on to develop psoriatic arthritis and therefore dermatologists are
in an ideal position to screen for psoriatic arthritis and provide
early therapeutic intervention or referral in order to prevent
disease progression."

The PRESTA study results demonstrated that Enbrel 50mg
once-weekly or twice-weekly provides improvement of skin symptoms
which continue to improve over time. In particular:

- At only 12 weeks, over half (55%) of patients taking Enbrel 50mg
twice-weekly and more than one third (36%) of patients taking Enbrel
50mg once-weekly showed a 75% improvement in the psoriasis
area-and-severity index (PASI 75)(1)
- After 24 weeks, over two thirds (70%) of patients taking Enbrel (50mg
twice-weekly for 12 weeks, followed by 50mg once-weekly for 12 weeks)
showed a 75% improvement in the psoriasis area-and-severity index
(PASI 75), demonstrating that skin clearance continues to improve with
Enbrel, even after Enbrel's dose is reduced(1)
- Almost two thirds (62%) of patients treated throughout with 50mg
once-weekly also went on to achieve PASI 75 by week 24(1)
- In addition, approximately three out of four patients (72-77%) taking
Enbrel showed joint improvement, as measured by the Psoriatic Arthritis
Response Criteria (PsARC), at only 12-weeks and maintained this
improvement at 24-weeks (shown in both arms of the study)(1)

Previous research has shown that the skin symptoms in psoriasis
patients are associated with a low quality of life comparable to, or
even worse than those individuals with other chronic medical
disorders, including heart disease(2). Further results from the
PRESTA study presented today demonstrate that Enbrel not only clears
skin, but can also improve patients' quality of life(3).

Professor Sterry concluded: "The PRESTA study confirms that
treating psoriatic arthritis early and aggressively with Enbrel can
effectively clear skin, providing patients with meaningful
improvements to their daily lives and offering the hope of preventing
irreversible damage to joints."

Both Enbrel dose regimens were well tolerated up to 24 weeks with
no new safety signals noted.

Enbrel has a long-established safety profile with over 16 years
of proven clinical experience, and is currently the number one
prescribed biologic worldwide.

To access further media information relating to this press
release, additional information on Enbrel and future media
announcements, please register on the media centre at
http://www.wyeth.eu. If you subscribe to receive our emails you will
get updates as soon as new content is added to the site. Please note
you will be able to unsubscribe at any time and we will not pass your
details to any third party.



This randomised, multicentre study enrolled patients with both
psoriasis and psoriatic arthritis from 110 global sites. In the
double-blind period, patients received either Enbrel 50mg twice
weekly (BiW) or 50mg once-weekly (QW) for 12 weeks; in the subsequent
open-label period, patients received 50mg once weekly for 12 weeks.

Please click here for study results.


Enbrel is a fully human soluble tumour necrosis factor (TNF)
receptor. Enbrel was first approved in 1998 for moderate to severe
rheumatoid arthritis and has since been administered to nearly
500,000 patients worldwide across indications.

Enbrel in the EU is approved for the following indications:

Rheumatoid arthritis

Enbrel in combination with methotrexate is indicated for the
treatment of moderate to severe active rheumatoid arthritis in adults
when the response to disease-modifying antirheumatic drugs, including
methotrexate (unless contraindicated), has been inadequate.

Enbrel can be given as monotherapy in case of intolerance to
methotrexate or when continued treatment with methotrexate is

Enbrel is also indicated in the treatment of severe, active and
progressive rheumatoid arthritis in adults not previously treated
with methotrexate.

Enbrel, alone or in combination with methotrexate, has been shown
to reduce the rate of progression of joint damage as measured by
X-ray and to improve physical function.

Polyarticular juvenile idiopathic arthritis

Treatment of active polyarticular juvenile idiopathic arthritis
in children and adolescents aged 4 to 17 years who have had an
inadequate response to, or who have proved intolerant of,
methotrexate. Enbrel has not been studied in children aged less than
4 years.

Psoriatic arthritis

Treatment of active and progressive psoriatic arthritis in adults
when the response to previous disease-modifying antirheumatic drug
therapy has been inadequate. Enbrel has been shown to improve
physical function in patients with psoriatic arthritis, and to reduce
the rate of progression of peripheral joint damage as measured by
X-ray in patients with polyarticular symmetrical subtypes of the

Ankylosing spondylitis

Treatment of adults with severe active ankylosing spondylitis who
have had an inadequate response to conventional therapy.

Plaque psoriasis

Treatment of adults with moderate to severe plaque psoriasis who
failed to respond to, or who have a contraindication to, or are
intolerant to other systemic therapy including cyclosporine,
methotrexate or PUVA


Wyeth is one of the world's largest research-based pharmaceutical
and health care products companies. It is a leader in the discovery,
development, manufacturing, and marketing of prescription drugs and
over-the-counter medications. It is also a global leader in vaccines,
biotechnology and animal health care.

(1) Poster P29 from the Gene to Clinic meeting, December 2008. Sterry. W.
et al. Results of a Randomized, Double-Blind Study to Evaluate the
Efficacy and Safety of Etanercept in Patients with Psoriasis and
Psoriatic Arthritis: The PRESTA Trial
(2) Richards HL et al. The contribution of perceptions of stigmatization
to disability in patients with psoriasis. J Psychosom Res.
(3) Poster P30 from the Gene to Clinic meeting, December 2008. Barker, J.
et all. Improvement in the Dermatology Life Quality Index for
Patients With Psoriasis and Psoriatic Arthritis Treated with

ots Originaltext: Wyeth Pharmaceuticals
Im Internet recherchierbar: http://www.presseportal.de

For further information, please contact: Wyeth: Gill Markham,
Communications - Europe, Middle East and Africa, Direct Tel:
+44-1628-692536, Email: markhagl@wyeth.com; Danielle Halstrom,
Communications - Global, Direct Tel: +1-484-865-2020, Email:
halstrd@wyeth.com; OgilvyHealthPR: Mary Barrington-Ward, Tel:
+44-207-108-6066, Email: mary.barrington-ward@ohpr.com; Nerea
Hinzpeter, Tel: +1-212-625-4178, Email: Nerea.hinzpeter@ohpr.com


Leider liegen uns zu diesem Artikel keine separaten Kontaktinformationen gespeichert vor.
Am Ende der Pressemitteilung finden Sie meist die Kontaktdaten des Verfassers.

Neu! Bewerten Sie unsere Artikel in der rechten Navigationsleiste und finden
Sie außerdem den meist aufgerufenen Artikel in dieser Rubrik.

Sie suche nach weiteren Pressenachrichten?
Mehr zu diesem Thema finden Sie auf folgender Übersichtsseite. Desweiteren finden Sie dort auch Nachrichten aus anderen Genres.


Weitere Informationen erhalten Sie per E-Mail unter der Adresse: info@bankkaufmann.com.

@-symbol Internet Media UG (haftungsbeschränkt)
Schulstr. 18
D-91245 Simmelsdorf

E-Mail: media(at)at-symbol.de


weitere Artikel:
  • Sparkassenverband Bayern empfiehlt erneut den Einsatz von FIOPORT Zahlungsverkehr Leipzig (ots) - Der Sparkassenverband Bayern hat sich erneut für den Einsatz der Softwarelösung FIOPORT ZAHLUNGSVERKEHR innerhalb der Sparkassen-Finanzgruppe Bayern ausgesprochen. Die webbasierte Softwarelösung der Leipziger FIO SYSTEMS AG, eines Sparkassen-Beteiligungsunternehmen, sei ein "geeignetes Instrument, um den Kunden die Abwicklung der Kautionszahlungen zu erleichtern und bei der Sparkasse Kosten zu reduzieren, heißt es in einem Ende November alle Verbandsmitglieder verschickten Rundschreiben. Seit der erstmaligen Empfehlung mehr...

  • Das Getriebe wird zum Treiber Pressebericht vom 7. Internationalen CTI Symposium "Innovative Fahrzeug-Getriebe" am 2. und 3. Dezember 2008 in Berlin Düsseldorf (ots) - - Automobilkrise dauert mindestens ein Jahr - Zukunftsrezept: Innovation plus Kooperation - Antriebstechnologie senkt Verbrauch und Emissionen - Benzinmotor bleibt langfristig erhalten Die Getriebeentwicklung kann für die Automobilindustrie eine Schlüsseltechnologie auf dem Weg aus der Krise und hin zu umweltfreundlichen Fahrzeugen sein. Die Branche ist darauf angewiesen, Innovationen jetzt schnell auf den Markt zu bringen. Hersteller und Zulieferer müssen künftig enger zusammenarbeiten, um die wirtschaftlichen, technischen mehr...

  • ECA International: Finanzkrise hat weltweit massive Auswirkungen auf die Lebenshaltungskosten - Berlin und München nun teuerer als London München (ots) - - Moskau überholt Oslo: Kostspieligstes Pflaster für ausländische Geschäftsleute in Europa - USA: Deutlicher Anstieg in den letzten beiden Monaten - Angolanische Hauptstadt Luanda bleibt teuerste Stadt der Welt Die weltweite Finanzkrise hat rund um den Globus massive Auswirkungen auf die Lebenshaltungskosten. So hat Moskau Oslo als teuerstes europäisches Pflaster verdrängt. Schuld daran sind primär die niedrigen Ölpreise, die die norwegische Währung schwächeln lassen. Das geht aus einer neuen Studie mehr...

  • Chemische Industrie stagniert im Jahr 2008 / VCI-Prognose: Produktion geht 2009 leicht zurück Frankfurt/Main (ots) - Die Folgen der Finanzkrise und des globalen Abschwungs hinterlassen auch in der chemischen Industrie deutliche Spuren. Die im zweiten Halbjahr immer schwächer werdende Nachfrage führte dazu, dass die Chemieproduktion seit dem zweiten Quartal rückläufig ist. Im vierten Quartal wurden sogar einzelne Produktionsanlagen stillgelegt. Im Gesamtjahr 2008 blieb die deutsche Chemieproduktion ohne Zuwachs. Der Verband der Chemischen Industrie (VCI) in Frankfurt geht davon aus, dass die Unternehmen ihre Produktionsanlagen zu mehr...

  • bet-at-home.com wird Hauptsponsor des rumänischen Handballverbandes Linz/Bukarest (ots) - bet-at-home.com und der rumänische Handballverband (RHF) haben eine Sponsoringvereinbarung unterzeichnet. Der internationale Online-Wettanbieter wird demnach sowohl als offizieller Hauptsponsor der rumänischen Damen- und Herren Nationalmannschaft, als auch als Namenssponsor der nationalen Damen- und Herren Liga auftreten. Die Zusammenarbeit wurde vorerst bis Ende 2009 vereinbart. Das börsennotierte Unternehmen, das bereits in der Spielsaison 2006/07 eine Kooperation mit der EHF Champions League einging, derzeit beim mehr...

Mehr zu dem Thema Aktuelle Wirtschaftsnews

Der meistgelesene Artikel zu dem Thema:

DBV löst Berechtigungsscheine von knapp 344 Mio. EUR ein

durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Sehr gut